CHAPPER healthcare has over 45 years’ experience in managing the supply of named patient medicines.
The supply of unlicensed medicines is highly regulated. However, in certain circumstances they can be supplied on a named-patient or managed access basis.
• If the product has yet to gain a licence for use in a specific disease area;
• If the product has yet to be licensed by the regulatory body;
• If the product is used to treat a rare disorder, often classified as an orphan drug.
We are able to offer named patient or managed access programmes, to meet the needs of all of our clients, utilising our infrastructure, including membership of our pan-European alliance (EuropAccess), and knowledge employed throughout our wholesale and distribution businesses.
Due to our long-established relationships with leading pharmaceutical suppliers, we are in a very strong position when it comes to supplying medicines, even highly restricted ones, on a named-patient basis.
Our staff are well aware that with managed access and named patient medicines, the health and wellbeing of an individual is dependent on their ability to supply the correct medicine at the correct time and they take great pride in ensuring that this happens.